Table 1.
Summarizes several cellular processes that can be therapeutically targeted.
| Drug/Therapeutic Target | Study/Year/Reference | Study Subjects | Pathway | Outcomes |
|---|---|---|---|---|
| Obeticholic acid | Huang S. (2021) [38] |
BMDM cells, hepatocytes/DIO + CCl4 mice | Inhibition of NLRP3 inflammasome activation in macrophages | Reduction in steatosis, fibrosis and immune infiltration |
| Inhibition of lipid-induced NLRP3 inflammasome activation in hepatocytes | ||||
| Antcin A | Ruan S. (2021) [39] |
KC cells/NAFLD mice | Inhibition of NLRP3 inflammasome activation in vitro/in vitro | Inhibition of immune infiltration |
| Auranofin | Hwangbo H. (2020) [40] |
High-fat diet (HFD) NAFLD model | Inhibition of NLRP3 inflammasome, NOX4 and PPARγ activation | Inhibition of immune infiltration |
| Cardiolipin inhibitors (shRNA-CLS1) | Liu J. (2019) [41] |
KC cells/methionine choline-deficient (MCD) diet mice | Inhibition of NLRP3 inflammasome activation in vitro/in vitro | Improvement in liver biochemistry |
| Cathepsin B inhibition | Tang Y. (2018) [42] |
KC cells/MCD diet NASH mice model | Inhibition of NLRP3 inflammasome activation | Inhibition of immune infiltration and steatosis |
| Polyunsaturated fatty acid (PUFA) | Sui Y. (2016) [43] |
HFD NASH mice model | Inhibition of NLRP3 inflammasome activation in vitro and in vivo | |
| Melatonin | Yu Y. (2021) [44] |
db/m mice, db/db mice | Improvement in mitochondrial membrane potential (MMP) | Reduction in steatosis, fibrosis and immune infiltration |
| Inhibition in NLRP3 inflammasome activation |